3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
46
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
40
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Gemcitabine
18
Specimen Handling
17
Lenalidomide
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Cyclosporine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
enzalutamide
×
90 days
×
Clear all
No trials found.